187 related articles for article (PubMed ID: 37702275)
41. Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study.
Charrua A; Pinto R; Taylor A; Canelas A; Ribeiro-da-Silva A; Cruz CD; Birder LA; Cruz F
Neurourol Urodyn; 2015 Jun; 34(5):489-96. PubMed ID: 24375689
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome.
Lim YN; Dwyer P; Murray C; Karmakar D; Rosamilia A; Thomas E
Int Urogynecol J; 2017 Jul; 28(7):1085-1089. PubMed ID: 27987022
[TBL] [Abstract][Full Text] [Related]
43. Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?
Kuo YC; Kuo HC
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999201
[TBL] [Abstract][Full Text] [Related]
44. Sensory Receptor, Inflammatory, and Apoptotic Protein Expression in the Bladder Urothelium of Patients with Different Subtypes of Interstitial Cystitis/Bladder Pain Syndrome.
Jiang YH; Jhang JF; Birder LA; Kuo HC
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614264
[TBL] [Abstract][Full Text] [Related]
45. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical OnabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis--clinical results and immunohistochemistry analysis.
Peng CH; Jhang JF; Shie JH; Kuo HC
Urology; 2013 Dec; 82(6):1452.e1-6. PubMed ID: 24295265
[TBL] [Abstract][Full Text] [Related]
46. A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome.
Chen CL; Kao CC; Yang MH; Fan GY; Cherng JH; Tsao CW; Wu ST; Cha TL; Meng E
Front Pharmacol; 2021; 12():755615. PubMed ID: 34975473
[TBL] [Abstract][Full Text] [Related]
47. Intravesical Botulinum Toxin A Injections for Bladder Pain Syndrome/Interstitial Cystitis: A Systematic Review and Meta-Analysis of Controlled Studies.
Wang J; Wang Q; Wu Q; Chen Y; Wu P
Med Sci Monit; 2016 Sep; 22():3257-67. PubMed ID: 27624897
[TBL] [Abstract][Full Text] [Related]
48. Sexual dysfunction in women with interstitial cystitis/bladder pain syndrome: Do onabotulinum toxin-A injections improve sexual function?
Topcuoglu M; Karaburun MC; İbiş A; Gokce Mİ; Süer E; Gülpinar O
Neurourol Urodyn; 2023 Mar; 42(3):607-614. PubMed ID: 36708358
[TBL] [Abstract][Full Text] [Related]
49. Biomaterial-assisted drug delivery for interstitial cystitis/bladder pain syndrome treatment.
Lin Z; Hu H; Liu B; Chen Y; Tao Y; Zhou X; Li M
J Mater Chem B; 2021 Jan; 9(1):23-34. PubMed ID: 33179709
[TBL] [Abstract][Full Text] [Related]
50. Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis.
Giannantoni A; Gubbiotti M; Bini V
Toxins (Basel); 2019 Aug; 11(9):. PubMed ID: 31480323
[TBL] [Abstract][Full Text] [Related]
51. The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis.
Jiang YH; Jhang JF; Kuo HC
Tzu Chi Med J; 2023; 35(1):31-37. PubMed ID: 36866354
[TBL] [Abstract][Full Text] [Related]
52. Protective Effect of Intravesical Platelet-Rich Plasma on Cyclophosphamide-Induced Hemorrhagic Cystitis.
Ozyuvali E; Yildirim ME; Yaman T; Kosem B; Atli O; Cimentepe E
Clin Invest Med; 2016 Dec; 39(6):27514. PubMed ID: 27917804
[TBL] [Abstract][Full Text] [Related]
53. Enhanced urothelial expression of human chorionic gonadotropin beta (hCGβ) in bladder pain syndrome/interstitial cystitis (BPS/IC).
Schwalenberg T; Stolzenburg JU; Ho TP; Mallock T; Hartenstein S; Alexander H; Zimmermann G; Hohenfellner R; Denzinger S; Burger M; Horn LC; Neuhaus J
World J Urol; 2012 Jun; 30(3):411-7. PubMed ID: 21877171
[TBL] [Abstract][Full Text] [Related]
54. Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition.
Jhang JF; Ho HC; Jiang YH; Lee CL; Hsu YH; Kuo HC
PLoS One; 2018; 13(6):e0198816. PubMed ID: 29879217
[TBL] [Abstract][Full Text] [Related]
55. Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease.
Jhang JF; Kuo HC
Int Neurourol J; 2016 Nov; 20(Suppl 2):S95-104. PubMed ID: 27915472
[TBL] [Abstract][Full Text] [Related]
56. Temperature-responsive silk-elastinlike protein polymer enhancement of intravesical drug delivery of a therapeutic glycosaminoglycan for treatment of interstitial cystitis/painful bladder syndrome.
Jensen MM; Jia W; Schults AJ; Isaacson KJ; Steinhauff D; Green B; Zachary B; Cappello J; Ghandehari H; Oottamasathien S
Biomaterials; 2019 Oct; 217():119293. PubMed ID: 31276948
[TBL] [Abstract][Full Text] [Related]
57. Intravesical instillation of platelet-rich plasma for treatment of interstitial cystitis/bladder pain syndrome: A pilot study.
El Hefnawy AS; Hasan MAA; El Sawy E; Abdel-Razik M; El-Tabey N
Curr Urol; 2024 Mar; 18(1):49-54. PubMed ID: 38505153
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play.
Ogawa T; Ishizuka O; Ueda T; Tyagi P; Chancellor MB; Yoshimura N
Expert Rev Clin Pharmacol; 2018 May; 11(5):495-505. PubMed ID: 29575959
[TBL] [Abstract][Full Text] [Related]
59. Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS).
Ogawa T; Ishizuka O; Ueda T; Tyagi P; Chancellor MB; Yoshimura N
Expert Opin Emerg Drugs; 2015; 20(4):555-70. PubMed ID: 26535808
[TBL] [Abstract][Full Text] [Related]
60. Botulinum Toxin A for Bladder Pain Syndrome/Interstitial Cystitis.
Chiu B; Tai HC; Chung SD; Birder LA
Toxins (Basel); 2016 Jul; 8(7):. PubMed ID: 27376330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
